AFP and hepatocellular carcinoma: In Japan and other parts of Asia, AFP is used in combination with AFP-L3% and DCP for HCC surveillance and the combined panel is studied in the context of overall, post-surgical, and recurrence-free survival outcomes [9,10,11,12,14,15,16,17].